AMR Action Fund
VC Fund
Boston, United States
AMR Action Fund is a VC fund in Boston focused on Biotechnology and Therapeutics. AMR Action Fund renders investment, healthcare, biotech, research and development, pharmaceutical, and antibiotic services. They invest in firms that are developing critical pathogen therapies and lobby for market reforms to transform how society values these lifesaving drugs. They aim to help launch two to four new antimicrobials over the nextdecade and build a sustainable investment environment.
- Total investments:
- 22
- Last investment:
- Lead investor:
- 82%
Last updated:
For AI agents: llms.txt
Industries AMR Action Fund invests in
BiotechnologyTherapeuticsHealth CareMedicalPharmaceutical
Stages AMR Action Fund invests in
Series BSeries CSeries ASeries ESeries H
Countries AMR Action Fund invests in
United StatesUnited KingdomSpainFranceIsrael
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Henry Skinner
|
|||
Sergei Petukhov
|
|||
3 more contacts available
Investment Focus
Industry
- Biotechnology 12 (55%)
- Therapeutics 8 (36%)
- Health Care 7 (32%)
- Medical 6 (27%)
- Pharmaceutical 5 (23%)
Stage
- Series B 4 (18%)
- Series C 3 (14%)
- Series A 2 (9%)
- Series E 2 (9%)
- Series H 1 (5%)
Country
- United States 7 (32%)
- United Kingdom 2 (9%)
- Spain 1 (5%)
- France 1 (5%)
- Israel 1 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Henry Skinner
Chief Executive Officer
|
Chief Executive Officer | Total investments: 18 | Find email | |
|
Sergei Petukhov
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Vedanta Biosciences
|
Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $40M / Venture - Series Unknown / Aug 06, 2026 | |
Trellis Bioscience
|
Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact ofpotential therapeutic interventions. The company is based in San Francisco, California. | $9M / Series C / Jul 16, 2026 | |
|
Trellis Bioscience
|
Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact ofpotential therapeutic interventions. The company is based in San Francisco, California. | $9M / Series C / Jul 16, 2026 | |
Telum Therapeutics
|
Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M / Series A / Jul 01, 2026 | |
Centauri Therapeutics
|
Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight theinfection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ strategy is to redirect naturally occurring antibodies to target disease. Centauri Therapeutics' unique Chemistry Platform provides a flexible scaffold to enable the synthesis of specific Alphamers. These are bifunctional molecules which present a selective cell binding moiety as well as an epitope that recruits pre-existing antibodies, resulting in cell killing. Centauri Therapeutics believes their technology is widely applicable in the treatment of life threatening infectious diseases. Companies with an interest in accessing Centauri’s Alphamer technology or with an interest in one of their current projects, are warmly encouraged to contact them to discuss partnering opportunities. In order to drive success in the important area of immuno-oncology, Centauri Therapeutics has established a joint venture, Avvinity Therapeutics, with Horizon Discovery in March 2016. Avvinity combines Centauri’s Alphamer Technology with the gene editing and oncology expertise of Horizon. In addition to Centauri Therapeutics' immuno-oncology joint venture, Centauri maintains a strong network of collaborators in the areas of aptamer selection, drug discovery, chemistry and immunology. | $8.1M / Series A / Feb 24, 2026 | |
|
Centauri Therapeutics
|
Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight theinfection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ strategy is to redirect naturally occurring antibodies to target disease. Centauri Therapeutics' unique Chemistry Platform provides a flexible scaffold to enable the synthesis of specific Alphamers. These are bifunctional molecules which present a selective cell binding moiety as well as an epitope that recruits pre-existing antibodies, resulting in cell killing. Centauri Therapeutics believes their technology is widely applicable in the treatment of life threatening infectious diseases. Companies with an interest in accessing Centauri’s Alphamer technology or with an interest in one of their current projects, are warmly encouraged to contact them to discuss partnering opportunities. In order to drive success in the important area of immuno-oncology, Centauri Therapeutics has established a joint venture, Avvinity Therapeutics, with Horizon Discovery in March 2016. Avvinity combines Centauri’s Alphamer Technology with the gene editing and oncology expertise of Horizon. In addition to Centauri Therapeutics' immuno-oncology joint venture, Centauri maintains a strong network of collaborators in the areas of aptamer selection, drug discovery, chemistry and immunology. | $8.1M / Series A / Feb 24, 2026 | |
Peptilogics
|
Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space but also ensuring that each potential therapeutic is biologically viable andscalable to manufacture. Peptilogics' lead clinical-stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need. | $78M / Series B / Oct 16, 2025 | |
TenNor Therapeutics
|
TenNor Therapeutics is a clinical stage, product development company with a sharp focus on unmet medical needs in the area of infectious diseases. The company possesses a dual-acting drug discovery platform with several innovative products in various stages of preclinical and clinical development. The company is developing new drugs for thetreatment of Helicobacter pylori infections, prosthetic joint infections, multidrug-resistant Gram-negative infections and some other common and serious infectious diseases. | $42.1M / Series E / Oct 16, 2024 | |
F2G
|
F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity. | $100M / Series H / Sep 12, 2024 | |
Elion Therapeutics
|
Elion Therapeutics is a cutting-edge biotechnology business focused on treating life-threatening IFIs. Elion was built on the notion that mechanistic insights allow for focused optimization of natural goods. | $81M / Series B / Jun 17, 2024 | |
| See all 22 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Health Care Investors
43,014 investors
Biotech Investors
21,775 investors
Biotechnology Investors
19,370 investors
Medical Investors
18,848 investors
Health Care VC Funds
32,370 investors
Biotech VC Funds
18,864 investors
Biotechnology VC Funds
17,016 investors
Medical VC Funds
16,214 investors
Health Care Investors in United States
21,541 investors
FAQ
What does AMR Action Fund invest in?
AMR Action Fund invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Series C stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact AMR Action Fund?
Public channels for AMR Action Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at AMR Action Fund?
The team at AMR Action Fund includes Henry Skinner (Chief Executive Officer) and Sergei Petukhov (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
